Trial results for a study investigating mHealth intervention strategies for Schizophrenia were posted on ClinicalTrials.gov on 2025-11-24, with 299 participants enrolled.
Background
Schizophrenia is a complex and chronic mental health condition characterized by a range of symptoms, including delusions, hallucinations, disorganized thinking, and impaired social functioning. Managing schizophrenia often requires long-term treatment, including medication and psychosocial interventions. Mobile health (mHealth) interventions, which leverage mobile devices and applications, present a potential avenue to enhance care delivery, support self-management, and improve access to mental health resources for individuals with schizophrenia, particularly within community mental health settings.
Trial design
This completed study, designated as Phase NA, enrolled 299 participants diagnosed with Schizophrenia. The trial was a randomized controlled study designed to examine two distinct mHealth intervention strategies: "External Facilitation" and "Internal Facilitation". The study aimed to compare the effectiveness of these two approaches in community mental health settings.
Key results
The trial collected mean scores for the Patient Health Questionnaire (PHQ)-9 and Generalized Anxiety Disorder-7 (GAD-7) for both intervention groups:
- Patient Health Questionnaire (PHQ)-9 scores (on scale):
- For the "External Facilitation" group, mean scores were 11.6 (Standard Error 0.5), 9.6 (Standard Error 0.6), and 9.3 (Standard Error 0.7).
- For the "Internal Facilitation" group, mean scores were 10.7 (Standard Error 0.6), 10.2 (Standard Error 0.7), and 9.4 (Standard Error 0.7).
- Generalized Anxiety Disorder-7 (GAD-7) scores (on scale):
- For the "External Facilitation" group, mean scores were 9.3 (Standard Error 0.5), 7.6 (Standard Error 0.6), and 7.9 (Standard Error 0.7).
- For the "Internal Facilitation" group, mean scores were 9 (Standard Error 0.6), 7.9 (Standard Error 0.6), and 7.6 (Standard Error 0.6).
Key analyses comparing the two mHealth intervention strategies using adjusted mixed-effects linear regression yielded the following difference-in-difference estimates:
- A difference-in-difference of 1.5 was observed for changes from baseline to 3 months, with a p-value of 0.06.
- A difference-in-difference of 1.0 was observed for changes from baseline to 6 months, with a p-value of 0.25.
- A difference-in-difference of 0.7 was observed for changes from baseline to 3 months, with a p-value of 0.37.
- A difference-in-difference of 0.6 was observed for changes from baseline to 6 months, with a p-value of 0.44.
- A difference-in-difference of -0.4 was observed for changes from baseline to 3 months, with a p-value of 0.619.
- A difference-in-difference of 1.5 was observed for changes from baseline to 6 months, with a p-value of 0.1.
What this means
The trial results provide data on the comparative effectiveness of two mHealth intervention strategies for individuals with schizophrenia in community mental health settings. While several difference-in-difference estimates were reported, the lowest p-value observed was 0.06 for a 3-month outcome, indicating a trend that did not meet conventional statistical significance thresholds. These findings suggest that further research may be warranted to explore the potential benefits of these mHealth facilitation strategies and to identify specific patient populations or implementation contexts where they might be most impactful. The observed mean scores for PHQ-9 and GAD-7 across both groups over time offer valuable insights into symptom trajectories under these interventions.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04147897, titled "Implementing mHealth for Schizophrenia in Community Mental Health Settings", were posted on 2025-11-24 on clinicaltrials.gov.